Quick Answer
Eledon Pharmaceuticals, Inc. reported Diluted EPS of $0.52 per share (loss) for fiscal year 2025.
Eledon Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.52 | +21.2% |
| 2024 | -$0.66 | +86.0% |
| 2023 | -$4.73 | +23.2% |
| 2022 | -$6.16 | -164.4% |
| 2021 | -$2.33 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.21 | +25.0% | -61.5% |
| June 30, 2025 | -$0.13 | +85.9% | -62.5% |
| March 31, 2025 | -$0.08 | +89.9% | +71.4% |
| September 30, 2024 | -$0.28 | +15.2% | +69.6% |
| June 30, 2024 | -$0.92 | +66.4% | -16.5% |
| March 31, 2024 | -$0.79 | -5.3% | -139.4% |
| September 30, 2023 | -$0.33 | +54.8% | +88.0% |
| June 30, 2023 | -$2.74 | -321.5% | -265.3% |
- Eledon Pharmaceuticals, Inc. showed an increase of +21.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Eledon Pharmaceuticals, Inc.’s diluted eps has grown by 77.7% (from $2.33 per share (loss) to $0.52 per share (loss)).
- The most recent figure is from Eledon Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: